32696016|t|Adjuvant Analgesic Use in the Critically Ill: A Systematic Review and Meta-Analysis.
32696016|a|This systematic review and meta-analysis addresses the efficacy and safety of nonopioid adjunctive analgesics for patients in the ICU. DATA SOURCES: We searched PubMed, Embase, the Cochrane Library, CINAHL Plus, and Web of Science. STUDY SELECTION: Two independent reviewers screened citations. Eligible studies included randomized controlled trials comparing efficacy and safety of an adjuvant-plus-opioid regimen to opioids alone in adult ICU patients. DATA EXTRACTION: We conducted duplicate screening of citations and data abstraction. DATA SYNTHESIS: Of 10,949 initial citations, we identified 34 eligible trials. These trials examined acetaminophen, carbamazepine, clonidine, dexmedetomidine, gabapentin, ketamine, magnesium sulfate, nefopam, nonsteroidal anti-inflammatory drugs (including diclofenac, indomethacin, and ketoprofen), pregabalin, and tramadol as adjunctive analgesics. Use of any adjuvant in addition to an opioid as compared to an opioid alone led to reductions in patient-reported pain scores at 24 hours (standard mean difference, -0.88; 95% CI, -1.29 to -0.47; low certainty) and decreased opioid consumption (in oral morphine equivalents over 24 hr; mean difference, 25.89 mg less; 95% CI, 19.97-31.81 mg less; low certainty). In terms of individual medications, reductions in opioid use were demonstrated with acetaminophen (mean difference, 36.17 mg less; 95% CI, 7.86-64.47 mg less; low certainty), carbamazepine (mean difference, 54.69 mg less; 95% CI, 40.39-to 68.99 mg less; moderate certainty), dexmedetomidine (mean difference, 10.21 mg less; 95% CI, 1.06-19.37 mg less; low certainty), ketamine (mean difference, 36.81 mg less; 95% CI, 27.32-46.30 mg less; low certainty), nefopam (mean difference, 70.89 mg less; 95% CI, 64.46-77.32 mg less; low certainty), nonsteroidal anti-inflammatory drugs (mean difference, 11.07 mg less; 95% CI, 2.7-19.44 mg less; low certainty), and tramadol (mean difference, 22.14 mg less; 95% CI, 6.67-37.61 mg less; moderate certainty). CONCLUSIONS: Clinicians should consider using adjunct agents to limit opioid exposure and improve pain scores in critically ill patients.
32696016	30	44	Critically Ill	Disease	MESH:D016638
32696016	199	207	patients	Species	9606
32696016	530	538	patients	Species	9606
32696016	726	739	acetaminophen	Chemical	MESH:D000082
32696016	741	754	carbamazepine	Chemical	MESH:D002220
32696016	756	765	clonidine	Chemical	MESH:D003000
32696016	767	782	dexmedetomidine	Chemical	MESH:D020927
32696016	784	794	gabapentin	Chemical	MESH:D000077206
32696016	796	804	ketamine	Chemical	-
32696016	806	823	magnesium sulfate	Chemical	MESH:D008278
32696016	825	832	nefopam	Chemical	MESH:D009340
32696016	882	892	diclofenac	Chemical	MESH:D004008
32696016	894	906	indomethacin	Chemical	MESH:D007213
32696016	912	922	ketoprofen	Chemical	MESH:D007660
32696016	925	935	pregabalin	Chemical	MESH:D000069583
32696016	941	949	tramadol	Chemical	MESH:D014147
32696016	1073	1080	patient	Species	9606
32696016	1090	1094	pain	Disease	MESH:D010146
32696016	1229	1237	morphine	Chemical	MESH:D009020
32696016	1423	1436	acetaminophen	Chemical	MESH:D000082
32696016	1514	1527	carbamazepine	Chemical	MESH:D002220
32696016	1614	1629	dexmedetomidine	Chemical	MESH:D020927
32696016	1707	1715	ketamine	Chemical	-
32696016	1794	1801	nefopam	Chemical	MESH:D009340
32696016	1997	2005	tramadol	Chemical	MESH:D014147
32696016	2186	2190	pain	Disease	MESH:D010146
32696016	2201	2215	critically ill	Disease	MESH:D016638
32696016	2216	2224	patients	Species	9606

